A5002568782- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Dementia and Cognitive Impairment Research
- Autism Spectrum Disorder Research
- Restless Legs Syndrome Research
- Cannabis and Cannabinoid Research
- Neurological diseases and metabolism
- Botulinum Toxin and Related Neurological Disorders
- Sleep and Wakefulness Research
- Neuroscience and Neuropharmacology Research
- Youth, Drugs, and Violence
- Mitochondrial Function and Pathology
- Psychology and Mental Health
- Nuclear Receptors and Signaling
- Alzheimer's disease research and treatments
- Genetic Associations and Epidemiology
- Ginkgo biloba and Cashew Applications
- Balance, Gait, and Falls Prevention
- Genomic variations and chromosomal abnormalities
- Lysosomal Storage Disorders Research
- Amyotrophic Lateral Sclerosis Research
- RNA regulation and disease
- CRISPR and Genetic Engineering
- Cerebral Palsy and Movement Disorders
Universidade de São Paulo
2016-2025
Universidade de Ribeirão Preto
2015-2025
Instituto de Neurociências e Comportamento
2013-2024
Clinics Hospital of Ribeirão Preto
2005-2024
Universidade Federal do Pará
2023
Weatherford College
2022
Universidade Brasil
2010-2022
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2019
Council of Science Editors
2016
Oklahoma State Department of Health
2015
The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is need new pharmacological intervention. Previously an antipsychotic neuroprotective effect Cannabidiol (CBD) suggested. Therefore, the aim present study was to directly evaluate first time, efficacy, tolerability safety CBD on PD patients with psychotic symptoms. This open-label pilot study. Six consecutive outpatients (four men two women) diagnosis who had at least 3...
Parkinson's disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, endocannabinoid system emerged as promising target.From sample 119 patients consecutively evaluated in specialized movement disorders outpatient clinic, we selected 21 without dementia or comorbid psychiatric conditions. Participants were assigned three groups seven subjects each who treated with placebo,...
What is known and objective Cannabidiol (CBD) the main non-psychotropic component of Cannabis sativa plant. REM sleep behaviour disorder (RBD) a parasomnia characterized by loss muscle atonia during associated with nightmares active dreaming. We have described effects CBD in RBD symptoms patients Parkinson's disease. Cases summary Four treated had prompt substantial reduction frequency RBD-related events without side effects. new conclusion This case series indicates that able to control RBD.
Although over 90 independent risk variants have been identified for Parkinson's disease using genome-wide association studies, most studies performed in just one population at a time. Here we large-scale multi-ancestry meta-analysis of with 49,049 cases, 18,785 proxy cases and 2,458,063 controls including individuals European, East Asian, Latin American African ancestry. In meta-analysis, 78 significant loci, 12 potentially novel loci (MTF2, PIK3CA, ADD1, SYBU, IRS2, USP8, PIGL, FASN, MYLK2,...
Background: Cannabidiol (CBD) is one of the main components Cannabis sativa and has anxiolytic properties, but no study been conducted to evaluate effects CBD on anxiety signs symptoms in patients with Parkinson’s disease (PD). This aimed impacts acute administration at a dose 300 mg measures tremors induced by Simulated Public Speaking Test (SPST) individuals PD. Methods: A randomised, double-blinded, placebo-controlled, crossover clinical trial was conducted. total 24 PD were included...
The use of cannabidiol in some neurological conditions was allowed by Conselho Regional de Medicina São Paulo and Agência Nacional Vigilância Sanitária (ANVISA). Specialists on behalf Academia Brasileira Neurologia prepared a critical statement about other cannabis derivatives diseases.
This work was undertaken in order to identify Parkinson's disease (PD) risk variants a Latino cohort, describe the overlap genetic architecture of PD Latinos compared European-ancestry subjects, and increase diversity genome-wide association (GWAS) data.We genotyped imputed 1,497 cases controls recruited from nine clinical sites across South America. We performed GWAS using logistic mixed models; with p-value <1 × 10-5 were tested replication cohort 1,234 self-reported 439,522 23andMe, Inc....
Abstract Background As gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction the estimated number subjects with monogenic PD worldwide currently represented in literature availability clinical data trial‐ready cohorts limited. Objective The objectives to (1) establish an international cohort affected unaffected individuals PD‐linked variants;...
Abstract After more than 200 years since its initial description, the clinical diagnosis of Parkinson's disease (PD) remains an often-challenging endeavor, with broad implications that are fundamental for management. Despite major developments in understanding it's pathogenesis, pathological landmarks, non-motor features and potential paraclinical clues, most accepted diagnostic criteria remain solidly based on a combination signs. Here, we review this process, discussing history, criteria,...
To determine the frequency of major sleep disorders in patients with Parkinson's disease (PD), diagnosed according to third international classification disorders, and assess relationship those quality life.A cross-sectional study was performed involving 88 consecutive PD from outpatient clinic. Participants were subjected clinical interviews, assessment using standardized scales (Epworth Sleepiness Scale, Questionnaire, Pittsburgh index (PSQI) and, for individuals a diagnosis RLS/WED,...
REM sleep behaviour disorder (RBD) is a common non-motor feature of Parkinson's disease (PD). Cannabidiol (CBD) one the main non-psychoactive components Cannabis sativa and may represent an alternative route for treating RBD.This study assessed efficacy safety CBD RBD in PD.We conducted phase II/III, double-blind, placebo-controlled clinical trial 33 patients with PD. Patients were randomized 1:1 to doses 75 300mg or matched capsules placebo followed up 14 weeks. The primary outcomes...
The Global Parkinson's Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic clinical data for use in large-scale analyses to dramatically expand our understanding of architecture PD. This report details workflow cohort integration into complex arm GP2, together with outline monogenic hub a companion paper, provides generalizable blueprint establishing large scale collaborative research consortia.
Cannabidiol (CBD), a Cannabis sativa constituent, may present pharmacological profile similar to mood stabilizing drugs, in addition anti-oxidative and neuroprotective properties. The study aims directly investigate the effects of CBD an animal model mania induced by d-amphetamine (d-AMPH). In first (reversal treatment), rats received saline or d-AMPH (2 mg/kg) once daily intraperitoneal (i.p.) for 14 days, from 8th 14th day, they were treated with (15, 30 60 i.p. twice day. second...
OBJECTIVE: To show data on the performance of healthy subjects in Frontal Assessment Battery (FAB), correlating with gender, age, education, and scores Mini-Mental State Examination (MMSE). METHODS: Two hundred seventy-five individuals mean age 66.4±10.6 years-old were evaluated. Mean total FAB established according to educational level. RESULTS: level 10.9±2.3, for one three years; 12.8±2.7, four seven 13.8±2.2, eight 11 15.3±2.3, 12 or more years. Total correlated significantly education...
Background: depression is common in Parkinson's disease (PD), although frequently under-recognised. Among the scales used to investigate depressive features PD, Patient Health Questionnaire-9 (PHQ-9) has been largely used, but no specific cut-off scores for have established thus far, which hinders use of PHQ-9 clinical and research settings. Objective: we assessed discriminant validity order establish best score diagnosis major PD patients. Method: one hundred ten patients with a without...
<strong>Background:</strong> Idiopathic focal dystonia is a motor syndrome associated with dysfunction of basal ganglia circuits. Observations have suggested that many other non-motor symptoms may also be part the clinical picture. The aim was to assess prevalence and correlation in patients common idiopathic or segmental dystonia. <strong>Methods:</strong> In single-center cross-sectional case–control study, we evaluated presence pain, neuropsychiatric symptoms, sleep alterations 28...
Abstract Background Sex differences in Parkinson's disease (PD) risk are well‐known. However, the role of sex chromosomes development and progression PD is still unclear. Objective The objective this study was to perform first X‐chromosome–wide association for a Latin American cohort. Methods We used data from three admixed cohorts: (1) Research consortium on Genetics Disease (n = 1504) as discover cohort, (2) Latino cohort International Parkinson Genomics Consortium 155) (3) Bambui Aging...
OBJECTIVE: Evaluate the accuracy of diagnosis major depression in patients with Parkinson's disease (PD) using UPDRS, 15-item Geriatric Depression Scale (GDS15) and Beck Inventory (BDI). METHOD: 50 consecutive PD were evaluated. The was made according to DSM-IV criteria. RESULTS: We found a 24% prevalence depression. All scales highly correlated but UPDRS item had lowest diagnostic value. GDS15 more appropriate "receiver operating characteristics" curve. best cut-off scores for screening...